News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
281,858 Results
Type
Article (14911)
Company Profile (299)
Press Release (266642)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (79837)
Career Advice (163)
Deals (13337)
Drug Delivery (39)
Drug Development (50705)
Employer Resources (31)
FDA (5839)
Job Trends (5169)
News (145088)
Policy (10072)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (920)
Accelerated approval (19)
Adcomms (14)
Allergies (85)
Alliances (21761)
ALS (126)
Alzheimer's disease (1035)
Antibody-drug conjugate (ADC) (244)
Approvals (6035)
Artificial intelligence (267)
Autoimmune disease (119)
Automation (9)
Bankruptcy (105)
Best Places to Work (4560)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (46)
Breast cancer (348)
Cancer (3163)
Cardiovascular disease (239)
Career advice (148)
Career pathing (8)
CAR-T (224)
CDC (5)
Cell therapy (576)
Cervical cancer (14)
Clinical research (43720)
Collaboration (1167)
Company closure (2)
Compensation (602)
Complete response letters (41)
COVID-19 (1101)
CRISPR (87)
C-suite (565)
Cystic fibrosis (112)
Data (4357)
Denatured (15)
Depression (93)
Diabetes (256)
Diagnostics (1383)
Digital health (13)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (196)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (218)
Earnings (31681)
Editorial (27)
Employer branding (4)
Employer resources (29)
Events (51709)
Executive appointments (628)
FDA (7605)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (10)
Frontotemporal dementia (22)
Funding (991)
Gene editing (184)
Generative AI (22)
Gene therapy (496)
GLP-1 (507)
Government (1149)
Grass and pollen (3)
Guidances (166)
Healthcare (6612)
HIV (18)
Huntington's disease (43)
IgA nephropathy (74)
Immunology and inflammation (194)
Immuno-oncology (43)
Indications (71)
Infectious disease (1211)
Inflammatory bowel disease (157)
Inflation Reduction Act (10)
Influenza (40)
Intellectual property (169)
Interviews (18)
IPO (7346)
IRA (13)
Job creations (867)
Job search strategy (130)
JPM (40)
Kidney cancer (9)
Labor market (23)
Layoffs (243)
Leadership (10)
Legal (1401)
Liver cancer (41)
Longevity (11)
Lung cancer (425)
Lymphoma (251)
Machine learning (24)
Management (7)
Manufacturing (380)
MASH (132)
Medical device (2666)
Medtech (2675)
Mergers & acquisitions (6623)
Metabolic disorders (733)
Multiple sclerosis (104)
NASH (13)
Neurodegenerative disease (233)
Neuropsychiatric disorders (70)
Neuroscience (1963)
Neurotech (1)
NextGen: Class of 2026 (2034)
Non-profit (867)
Now hiring (31)
Obesity (333)
Opinion (125)
Ovarian cancer (132)
Pain (102)
Pancreatic cancer (165)
Parkinson's disease (232)
Partnered (12)
Patents (305)
Patient recruitment (344)
Peanut (44)
People (26686)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15492)
Phase 2 (20314)
Phase 3 (12829)
Pipeline (3350)
Policy (91)
Postmarket research (853)
Preclinical (6540)
Press Release (30)
Prostate cancer (147)
Psychedelics (50)
Radiopharmaceuticals (239)
Rare diseases (660)
Real estate (1448)
Recruiting (12)
Regulatory (9920)
Reports (19)
Research institute (973)
Resumes & cover letters (19)
Rett syndrome (24)
RNA editing (21)
RSV (17)
Schizophrenia (124)
Series A (184)
Series B (140)
Service/supplier (1)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2006)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (340)
Venture capital (69)
Weight loss (174)
Women's health (26)
Worklife (2)
Date
Today (78)
Last 7 days (302)
Last 30 days (1162)
Last 365 days (17862)
2026 (1947)
2025 (18098)
2024 (20543)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23356)
2019 (16223)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (154)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18272)
Australia (3114)
California (7139)
Canada (1855)
China (783)
Colorado (249)
Connecticut (255)
Delaware (236)
Europe (39207)
Florida (911)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (398)
India (36)
Indiana (162)
Iowa (8)
Japan (227)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (740)
Massachusetts (5627)
Michigan (110)
Minnesota (250)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (33)
New Hampshire (21)
New Jersey (1657)
New Mexico (13)
New York (1774)
North Carolina (836)
North Dakota (6)
Northern California (3515)
Ohio (179)
Oklahoma (11)
Oregon (24)
Pennsylvania (1287)
Puerto Rico (9)
Rhode Island (25)
South America (215)
South Carolina (9)
Southern California (2830)
Tennessee (40)
Texas (918)
United States (23523)
Utah (97)
Virginia (137)
Washington D.C. (37)
Washington State (593)
West Virginia (1)
Wisconsin (46)
281,858 Results for "jounce therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
NeuroEM Therapeutics(R) Appoints Dr. W. Scott Burgin as Chief Medical Officer
February 1, 2026
·
2 min read
Business
Jounce Therapeutics Announces Restructuring - February 22, 2023
Jounce Therapeutics, Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced that it is reducing its workforce by approximately 57 percent.
February 22, 2023
·
4 min read
Deals
Concentra’s Buy Offer May Jeopardize Jounce’s Merger with Redx
Jounce Therapeutics has received an unsolicited and non-binding acquisition proposal from Concentra Biosciences, looking to buy 100% of Jounce’s equity at a per-share price of $1.80 in cash.
March 15, 2023
·
2 min read
·
Tristan Manalac
Deals
Redx and Jounce Announce Recommended Business Combination
Redx Pharma and Jounce Therapeutics, Inc. announce an unanimously recommended Business Combination of the two companies via a proposed all share merger transaction.
February 23, 2023
·
19 min read
Genetown
Jounce Therapeutics to Present at Upcoming Investor Conferences - May 17, 2022
Jounce Therapeutics, Inc. announced that Jounce management will participate at the following upcoming investor conferences:
May 17, 2022
·
2 min read
Business
Jounce Therapeutics Reports Third Quarter 2022 Financial Results
Jounce Therapeutics, Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.
November 10, 2022
·
13 min read
Genetown
Jounce Therapeutics to Participate in the Upcoming September 2022 Investor Conferences
Jounce Therapeutics, Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced that company management will participate in the following upcoming investor conferences in September.
September 7, 2022
·
2 min read
Deals
Jounce Slashes 57% of Staff, Drops Assets in Stock Merger with Redx
One day after revealing a restructuring initiative, Jounce Therapeutics announced it plans to merge its business in an all-stock deal with clinical-stage biotech Redx Pharma.
February 23, 2023
·
1 min read
·
Rosemary Scott
Business
Jounce Therapeutics Reports First Quarter 2022 Financial Results
Jounce Therapeutics, Inc. today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.
May 5, 2022
·
11 min read
Deals
Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics
Gilead Sciences, Inc. and Jounce Therapeutics, Inc. amended their existing license agreement for GS-1811, enabling Gilead to buy out remaining contingent payments potentially due under the license agreement executed in August 2020.
December 27, 2022
·
7 min read
1 of 28,186
Next
